Lilly silent on retatrutide access after single-patient OK
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly granted a single 79-year-old patient special access to retatrutide, an unapproved obesity drug that has shown bariatric-surgery-level weight loss, as STAT first reported last month.
- At least a handful of clinicians have since tried to obtain the same access for their own patients following that report.
- Two of those clinicians have received no response from Lilly for weeks, according to STAT.
- One physician only heard back on Monday — after STAT reached out to Lilly with questions for this story — and was told his patient might qualify for access to the drug.
- Doctors are now publicly calling on Lilly to clarify whether it plans to expand access to retatrutide or whether the single-patient approval was a one-time special circumstance.
- The opacity is fueling new questions about why Lilly gave extraordinary access to one experimental obesity drug patient in the first place.
Why it matters: Lilly's silence toward other requesting physicians — and its responsiveness only after a reporter called — turns what was framed as a compassionate single-patient decision into an opaque gatekeeping decision for an experimental therapy other doctors argue their patients need.
